18 results about "Intraperitoneal injection" patented technology

The present application belongs to the field of microbial technology, and particularly relates to a bacteriophage preparation for controlling foodborne enterobacter and application thereof, wherein the bacteriophage preparation comprises any one or several of bacteriophage PhiEAS1, bacteriophage PhiEHO11, bacteriophage PhiEHO14 and bacteriophage PhiECL22. The four bacteriophages provided by the present application can be used alone or combined into a bacteriophage cocktail, and the influence of the bacteriophage preparation on enterobacter in different ecologies and environments is explored through bacteriophage cocktail therapy. The results show that the bacteriophage preparation exhibits significant bacteriostatic activity on various food substrates contaminated by Enterobacter hormaechei, such as lettuce, pork, milk, cherry tomato and the like; in an animal model, intraperitoneal injection of the bacteriophage preparation can effectively prevent and treat bacteremia caused by Enterobacter hormaechei, and shows potential as an anti-Enterobacter hormaechei biological control agent.

This invention relates to the application of PGG in the preparation of drugs for treating acute leukemia, belonging to the field of biomedical technology. To address the problems of narrow application range and easy development of drug resistance in existing acute leukemia treatments, this invention provides the application of PGG in the preparation of drugs for treating acute leukemia. Experiments have shown that PGG can inhibit the viability, proliferation, and colony formation of human acute myeloid leukemia cells (MOLM-13) and human acute lymphoblastic leukemia cells (Jurkat), and induce their apoptosis. In animal models, intraperitoneal injection of PGG can prolong the survival days of mice with acute leukemia and reduce the infiltration of leukemia cells in the liver, spleen, and bone marrow tissues. In this invention, PGG directly inhibits the viability of acute leukemia cells and can simultaneously inhibit AML and ALL, without relying on specific gene mutations, resulting in a lower risk of drug resistance, more flexible clinical use, and broader patient coverage, showing promising clinical application prospects.

The application discloses a rat fixing device based on biological evaluation of medical instruments. The device comprises an operation panel, a fixing cover, a sliding sheet and a sliding groove. A rectangular opening is designed in the center of the base of the operation panel, which is specially used for abdominal cavity injection operation of rats. The rat fixing cover is divided into four sections and is arranged on the operation panel. The two sides of the fixing cover are provided with the sliding sheets. The shape of the two sliding sheets after being spliced together is the same as that of the fixing cover. The lower end of the sliding sheet is in contact with the operation panel, and the sliding groove is arranged at the contact part. The rat fixing device can effectively adjust the size, so that rats with different body types can be effectively fixed, and the smooth operation of the test is ensured. The device is convenient to operate and stable in rat fixing.

This invention discloses a live attenuated vaccine for the prevention of Toxoplasma gondii infection, the active ingredient of which is the tachyzoite of the Toxoplasma gondii RHΔpCaBp1 gene knockout strain. This invention prepares a live attenuated RHΔpCaBp1 vaccine that can be used to prevent Toxoplasma gondii infection in intermediate hosts. Immunization with this live attenuated vaccine, containing 100 Toxoplasma gondii RHΔpCaBp1 tachyzoites, via intraperitoneal injection, showed safety in mice after three immunizations, and demonstrated 100% protection against low-dose virulent strains (intraperitoneal injection of 100 and 500 RH tachyzoites) in the model intermediate host.

The application discloses a method for establishing a Bama miniature pig spleen deficiency and dampness excess model, and belongs to the technical field of animal models. The method is to reduce the immunity of the body by intraperitoneal injection of cyclophosphamide, and then to stimulate the Bama miniature pig by using high-sugar and high-fat feed and senna leaves in combination with a high-humidity external environment. After 8 weeks, the Bama miniature pig has the clinical manifestations of the spleen deficiency and dampness excess, such as body fatness, fatigue and laziness, white and slippery tongue fur, and loose and watery stool, and the model is verified in the reverse direction by using the classic compound Shenglin Bai Zhusan. The Bama miniature pig spleen deficiency and dampness excess model is applied to the research of human spleen deficiency and dampness excess and the development of spleen-invigorating and dampness-expelling drugs. The model provides a new model for standardizing, standardizing and scientifically evaluating the research of spleen-invigorating and dampness-expelling traditional Chinese medicines, and has the advantages of good practicability, strong conformity, simplicity and objectivity, and conforms to the guidance of the theory of traditional Chinese medicine syndromes, and has a wide application prospect.

The application belongs to the technical field of biological medicine, and specifically discloses application of jatrorrhizine in preparation of a medicine for preventing and treating intestinal radiation injury, and a medicine for preventing and treating intestinal radiation injury.The application verifies the effect of jatrorrhizine on resisting intestinal radiation injury by using an intestinal organ model, wherein the jatrorrhizine can obviously improve the changes in survival rate, bud number and organ size of the intestinal organ caused by radiation injury, and eliminate the adverse effects caused by the intestinal radiation injury.After abdominal irradiation injury of experimental mice, jatrorrhizine is injected into the abdominal cavity, the intestinal length is obviously increased, the survival rate is improved, and HE staining of small intestinal sections shows that the crypt depth and villus structure are improved.It is proved that the jatrorrhizine can promote the regeneration and repair of the intestinal organ after radiation, improve the survival rate, and improve the morphological changes of the intestinal caused by radiation injury.The medicine containing the jatrorrhizine provided by the application can improve the intestinal lesions caused by radiation injury, relieve the intestinal injury symptoms, and improve the survival rate of individuals.

The application discloses an antagonistic bacterium of pathogenic shewanella of Apostichopus japonicus and application thereof, and belongs to the technical field of aquatic microorganisms. Gilvus japonicus The antagonistic bacterium is separated from the intestinal tract of healthy Apostichopus japonicus and is identified as Japanese Yellow Sea Oceanic Bacterium (Shewanella japonica), has no beta-hemolysis characteristic, is safe and non-toxic to Apostichopus japonicus, and can significantly antagonize the pathogenic bacterium Shewanella of Apostichopus japonicus skin rot syndrome. The application also discloses application of the antagonistic bacterium, which can be prepared into an aquatic microecological preparation for preventing and treating the skin rot syndrome of Apostichopus japonicus, and is applied through intraperitoneal injection or immersion, so that the survival rate of Apostichopus japonicus under exposure of the pathogenic bacterium is significantly improved. The strain has strong salt and alkali resistance, tolerances to various antibiotics and chemical drugs, and strong environmental adaptability, can be applied to the cultivation of Apostichopus japonicus to replace traditional antibiotics, effectively solves the problems of food safety and environmental pollution caused by the abuse of antibiotics, and has good industrial application prospect.

The application provides application of idebenone in preparation of a medicine for treating osteosarcoma. The application of idebenone or a pharmaceutically acceptable salt thereof in preparation of the medicine for treating osteosarcoma is achieved by carrying out proliferation experiments (CCK8 method) and invasion experiments (transwell invasion experiment) of osteosarcoma cell lines in vitro, quantitative analysis of cell viability in the CCK8 method proliferation experiment and quantitative analysis of the number of penetrated cells in the transwell invasion experiment; and constructing a nude mouse CDX (cell-derived xenograft) model, a PDX (human-derived xenograft) model and a tibial orthotopic / metastatic tumor model, intraperitoneally injecting idebenone, and quantitatively analyzing the tumor volume and tumor weight in the CDX model, the tumor volume and tumor weight in the PDX model and the tumor volume, the weight of the affected limb and the number of lung metastases in the tibial orthotopic / metastatic tumor model, which fully indicates that idebenone can inhibit the proliferation, invasion and metastasis of osteosarcoma.

The application provides a method for establishing a subacute cerebellar ataxia animal model and application. Specifically, a method for establishing a subacute cerebellar ataxia animal model based on a low-dose staged increasing administration mode of a compound preparation of talipexole and application thereof are provided. The application induces mice to have pathological characteristics such as movement coordination disorders, cerebellar volume atrophy and Purkinje cell loss under the premise of ensuring the survival rate of animals by intraperitoneal injection of Zoletil 50 for several weeks. The model has high stability, good repeatability and controllable damage degree, and can be used for anti-ataxia drug screening and neuroprotective mechanism research.

This invention discloses a method for establishing a model of oligoasthenospermia using trimethylamine N-oxide. The method involves injecting trimethylamine N-oxide into the peritoneal cavity of an animal to obtain the oligoasthenospermia model. This invention successfully established a mouse model of oligoasthenospermia by intraperitoneal injection of trimethylamine N-oxide (TMAO) into male mice. This provides new ideas and clues for in-depth research on the pathogenesis of oligoasthenospermia and for researchers studying male reproductive health. It also has significant scientific and medical value for understanding the pathogenesis of male infertility, developing new therapies, evaluating treatment effects, and promoting related clinical research.

The invention discloses application of melatonin in anti-inflammatory intervention of bilirubin encephalopathy, and the melatonin relieves neuroinflammation of the bilirubin encephalopathy by inhibiting activation of NLRP3 inflammasome, reducing GSDMD splitting decomposition and reducing the levels of proinflammatory factors TNF-alpha, IL-6 and IL-1beta and depending on a PI3K / AKT signal channel; the administration dosage of the melatonin is 10-20 mg / kg of body weight; the medicine is administrated through intraperitoneal injection; the melatonin plays an anti-inflammatory role by inhibiting the activation of NLRP3 inflammasome; the melatonin plays an anti-inflammatory role by reducing splitting decomposition of the GSDMD; the medicine further comprises a pharmaceutically acceptable carrier. The invention provides a new anti-inflammatory treatment strategy except for reducing bilirubin for the bilirubin encephalopathy.

This invention discloses the application of ML-SA5, a highly specific small molecule agonist of TRPML1, for the preparation of drugs against aortic aneurysms or aortic dissections. An aortic aneurysm model was constructed, and an aortic dissection model was established using Fbn1 point mutations. The severity of aortic aneurysms or aortic dissections in control and experimental mice was assessed using small animal ultrasound and aortic morphology staining. Results showed that intraperitoneal injection of ML-SA5 or overexpression of TRPML1 significantly reduced abdominal aortic aneurysm / dissection lesions in mice; it also reduced elastic fiber degradation and smooth muscle cell destruction in abdominal aortic aneurysms, decreased the increase in media thickness and collagen fiber deposition in aortic dissections, further improving the progression and histopathological damage of abdominal aortic aneurysms / dissections. This drug showed good therapeutic effects in animal experiments, with high safety and few toxic side effects, and can be used as a drug to inhibit the progression of aortic aneurysms / dissections.

This invention discloses the application of SB202190 in the preparation of drugs for treating immune checkpoint inhibitor-associated pneumonia (CIP), belonging to the field of pharmaceutical technology. It also discloses related screening methods, model construction methods, and synergistic anti-tumor applications. A CIP mouse model was constructed based on an LLC orthotopic lung cancer model using intraperitoneal injection of a PDL1 monoclonal antibody. Experiments confirmed that SB202190 can inhibit p38 MAPK activity, block abnormal activation of the NF-κB pathway, reduce T cell, neutrophil, and macrophage infiltration, decrease the release of inflammatory factors such as IFN-γ and IL17A, and alleviate pathological damage to lung tissue. When SB202190 is used in combination with anti-tumor drugs, its antitumor activity is not reduced; instead, it synergistically exerts an anti-tumor effect, making it suitable for the treatment of CIP in cancer patients who develop the disease after using immune checkpoint inhibitors. This invention provides a new technical approach and solution for the treatment of CIP.

The application belongs to the field of clinical drug toxic side effects, and particularly relates to the use of phenazine-1-carboxylic acid in treating cisplatin-mediated acute kidney injury. The application first discovers and proves that phenazine-1-carboxylic acid can effectively alleviate cisplatin-induced acute kidney injury. In a cisplatin-induced acute kidney injury model of mice, intraperitoneal injection of phenazine-1-carboxylic acid can effectively protect kidney function, which is specifically manifested as follows: significantly reducing urea nitrogen and creatinine levels in serum of model mice; reducing pathological injury of kidney tissue and reducing tubular injury score; and inhibiting expression of inflammatory factors and injury markers in kidney tissue. The treatment effect is equivalent to that of a classic ferroptosis inhibitor, Ferrostatin-1, and a new candidate drug for solving the dose-limiting toxicity of cisplatin in clinical application is provided.

The present application relates to the use of fungacin in the construction of an animal model of implantation disorder and a method for constructing an animal model of implantation disorder, and belongs to the technical field of medicine. The present application manufactures an SD rat implantation disorder TCM syndrome combination model conforming to the kidney deficiency and blood stasis syndrome type, meeting the needs of TCM research; a stable kidney deficiency and blood stasis-embryo implantation disorder rat model is manufactured, and the success rate of modeling is improved; the modeling time of the present application is only 5 days from confirming that the rat is pregnant, greatly reducing the modeling time; the operation steps are reduced, and only one intraperitoneal injection is needed to complete, reducing the harm to experimental animals.

The application provides a vaccine against ichthyophthiriasis and a preparation method and application thereof, and belongs to the technical field of fish disease prevention and control. The application uses inactivated whole worms of in-vitro large-scale cultured Amphilina alata as a cross antigen, and fish complement C5a protein as an immunoadjuvant, and the two synergistically play a high-efficiency immune protection role. The application mixes and emulsifies the C5a adjuvant and the antigen at an effective dose of 1x10 4 6x10 4 per tail to prepare the vaccine. After intraperitoneal injection and secondary boosting, the vaccine produces significant cross protection against the infection of the ichthyophthirius, and the protection effect is significantly better than that of a traditional Freund's adjuvant vaccine. The application breaks the bottleneck that the ichthyophthirius cannot be cultured in vitro and thus a large number of worm bodies cannot be obtained for large-scale preparation of whole worm vaccines, and also solves the problem of poor safety of traditional adjuvants, has the advantages of low cost, good effect, easy large-scale production and the like, and is suitable for green immune prevention and control of ichthyophthiriasis of freshwater fish.

The application belongs to the technical field of biological medicine, and relates to application of FcRn inhibitor efgartid in preparation of a medicine for treating Alzheimer's disease. In-vivo experiments prove that after abdominal cavity injection of APP / PS1 mice, the injection frequency is once a week, the injection lasts for four weeks, the injection dose is 10 mg / kg, and the efgartid can significantly reduce the serum IgG level of the APP / PS1 mice, relieve cerebral A beta pathological deposition, and reduce disease-related neuroinflammation and Tau protein phosphorylation. The application provides a new way for treating Alzheimer's disease.